Skip to Content
Shadow

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Agile Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Second Consecutive Quarter of Increase in Twirla Demand and Decrease in Company Operating Expenses Cash on Hand Expected to Fund Operations Through 2022 Company Announces Twirla ® Product Supply Agreement with Nurx Management to Host Conference Call Today, Thursday, August 11, 2022 at 4:30 p.m....
Toggle Summary Agile Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on Thursday, August 11, 2022
Live Conference Call and Webcast at 4:30 p.m. ET PRINCETON, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report second quarter 2022 financial results after the market close on Thursday, August 11, 2022....
Toggle Summary Agile Therapeutics Updates Second Quarter 2022 Guidance
Twirla® Demand Guidance (Total Cycles) Expected to be at Midpoint of Guided Range Operating Expenses (OPEX) Expected to be Below Guided Range PRINCETON, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that it has updated its...
Toggle Summary Agile Therapeutics to Participate in Maxim Group’s Upcoming Women’s Health Panel
PRINCETON, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be participating in a virtual panel discussion presented by Maxim Group LLC and hosted by M-Vest....
Toggle Summary Agile Therapeutics Announces Closing of $24 Million Upsized Public Offering
PRINCETON, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the closing of its previously announced upsized public offering of an aggregate of 26,666,666 shares of its common stock...
Toggle Summary Agile Therapeutics Announces Pricing of $24 Million Upsized Public Offering
PRINCETON, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the pricing of its upsized public offering of an aggregate of 26,666,666 shares of its common stock (or pre-funded...
Toggle Summary Agile Therapeutics to Present at The H.C. Wainwright Global Investment Conference
PRINCETON, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that Al Altomari, Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference taking place May 23-May 26, 2022 in Miami, FL....
Toggle Summary Agile Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Twirla Experienced Another Quarter of Double-Digit Demand Growth in First Quarter 2022 Twirla Business Plan Progressing Company Anticipates Future 2022 Quarterly Operating Expenses to be Lower Management to Host Conference Call Today, Thursday, May 12, 2022 at 4:30 p.m....
Toggle Summary Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentation
PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today publicly released the findings of its first year of post-marketing pharmacovigilance safety surveillance for Twirla ® (levonorgestrel and ethinyl estradiol) transdermal...
Toggle Summary Agile Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on Thursday, May 12, 2022
Live Conference Call and Webcast at 4:30 p.m. ET PRINCETON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report first quarter 2022 financial results after the market close on Thursday, May 12, 2022....
Shadow